Claims
- 1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a hypotriglyceridemically effective amount of an isolated compound, or a pharmaceutically acceptable salt thereof, having the formula:
- 2. The composition of claim 1, wherein R1 is selected from the group consisting of H, OH, methoxy, and ethoxy.
- 3. The composition of claim 1, wherein R2 is selected from the group consisting of C1-11 alkyl and C2-11 alkenyl.
- 4. The composition of claim 3, wherein R2 is selected from the group consisting of C1-6 alkyl, and C2-6 alkenyl.
- 5. The composition of claim 1, wherein R3 is selected from the group consisting of H, OH, methoxy, and ethoxy.
- 6. The composition of claim 1, wherein R4 is selected from the group consisting of C1-11 alkyl and C2-11 alkenyl.
- 7. The composition of claim 6, wherein R4 is selected from the group consisting of C1-6 alkyl, and C2-6 alkenyl.
- 8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a hypotriglyceridemically effective amount of an isolated compound, or a pharmaceutically acceptable salt thereof, having the formula:
- 9. The composition of claim 1, wherein said compound is selected from the group consisting of:
(A) 3-hydroxy-4-(3-methyl-2-butenyl)-5-methoxystilbene-2-carboxylic acid; (B) 3-hydroxy-6-(3-methyl-2-butenyl)-5-methoxystilbene-2-carboxylic acid; (C) 4-(3-methyl-2-butenyl)-3,5-dimethoxystilbene-2-carboxylic acid; (D) 6-(3-methyl-2-butenyl)-3,5-dimethoxystilbene-2-carboxylic acid; (E) 3,4′-dihydroxystilbene-2-carboxylic acid; (F) 3,5-dihydroxystilbene-2-carboxylic acid; (G) 3-hydroxy-4-(3-methyl-2-butenyl)-5-methoxybibenzyl-2-carboxylic acid; (H) 3,4′-dihydroxybibenzyl-2-carboxylic acid; and (I) 3,5-dihydroxy-4-(3-methyl-2-butenyl)bibenzyl-2-carboxylic acid.
- 10. A method of lowering serum triglycerides in a mammal in need thereof comprising administration of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a hypotriglyceridemically effective amount of an isolated compound or apharmaceutically acceptable salt thereof, having the formula:
- 11. The method of claim 10, wherein said mammal has type I diabetes.
- 12. The method of claim 10, wherein said mammal has type II diabetes.
- 13. The method of claim 10, wherein said mammal is suffering from obesity.
- 14. The method of claim 10, wherein said mammal has atherosclerotic cardiovascular disease.
- 15. The method of claim 11, wherein said compound is administered with at least one other blood-glucose lowering or fatty acid lowering compound.
- 16. The method of claim 12, wherein said compound is administered with at least one other blood-glucose lowering or fatty acid lowering compound.
- 17. The method of claim 13, wherein said com pound is administered with at least one other blood-glucose lowering or fatty acid lowering compound.
- 18. The method of claim 14, wherein said compound is administered with at least one other compound selected from the group consisting of: (A) fibrates; (B) HMG-CoA reductase inhibitors; (C) inhibitors of cholesterol absorption; (D) Squalene synthesis inhibitors; (E) LDL catabolism enhancers; and (F) Angiotensin converting enzyme inhibitors.
- 19. The method of claim 10, wherein said hypotriglyceridemically effective amount of said compound is about 1 to about 1000 mg/kg/day.
- 20. The method of claim 19, wherein said hypotriglyceridemically effective amount of said compound is between about 50 to about 350 mg/kg/day.
- 21. The method of claim 10, wherein said composition is administered orally.
- 22. The method of claim 10, wherein said compound is isolated from Cajanus cajan.
- 23. The method of claim 10, wherein said pharmaceutically acceptable salt is selected from the group consisting of sodium, potassium, lithium, calcium, magnesium, zinc and iron.
- 24. The method of claim 10, wherein said compound is selected from the group consisting of:
(A) 3-hydroxy-4-(3-methyl-2-butenyl)-5-methoxystilbene-2-carboxylic acid; (B) 3-hydroxy-6-(3-methyl-2-butenyl)-5-methoxystilbene-2-carboxylic acid; (C) 4-(3-methyl-2-butenyl)-3,5-dimethoxystilbene-2-carboxylic acid; (D) 6-(3-methyl-2-butenyl)-3,5-dimethoxystilbene-2-carboxylic acid; (E) 3,4′-dihydroxystilbene-2-carboxylic acid; (F) 3,5-dihydroxystilbene-2-carboxylic acid; (G) 3-hydroxy-4-(3-methyl-2-butenyl)-5-methoxybibenzyl-2-carboxylic acid; (H) 3,4′-dihydroxybibenzyl-2-carboxylic acid; and (I) 3,5-dihydroxy-4-(3-methyl-2-butenyl)bibenzyl-2-carboxylic acid.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims priority to U.S. Provisional Application Ser. No. 60/225,704, filed Aug. 16, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60225704 |
Aug 2000 |
US |